A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants With Moderately to Severely Active Ulcerative Colitis
- Colitis Ulcerative
- Ulcerative Colitis
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Merck Sharp & Dohme LLC
- Enrolment target
- 100
- Started
- 24 March 2026
- Main results due
- 28 October 2027
- Study sites
- 38
- Registry updated
- 28 September 2026
Can you take part?
- Ages 18 years to 75 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
The main inclusion criteria include but are not limited to the following: * Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before Randomization * Has moderately to severely active UC * Has a weight ≥40 kg * Satisfies at least 1 of the criteria: Has had an inadequate response or loss of response to 1 or more protocol-specified treatments; protocol specified corticosteroid dependence; has been intolerant to 1 or more protocol-specified UC treatments * Is on treatment with any protocol-specified drugs during the study and meets drug stabilization requirements, as applicable The main exclusion criteria include but are not limited to the following: * Has a diagnosis of Crohn's Disease (CD) or indeterminate colitis (inflammatory bowel disease (IBD)-undefined) or other types of colitis or enteritis that may confound efficacy assessment * Has a current diagnosis of fulminant colitis and/or toxic megacolon * Has UC limited to the rectum * Has a current or impending need for colostomy or ileostomy * Has had a total proctocolectomy or partial colectomy * Has UC exacerbation requiring hospitalization within 2 weeks before Screening * Has any active infection as specified in the protocol * Is known to be infected with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) * Has evidence of active tuberculosis (TB) or meets TB exclusionary parameters * Has a history of cancer (except fully treated nonmelanoma skin cell cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \<5 years before Randomization or has a history of colorectal cancer at any time * Has prior or current evidence of definite colonic dysplasia except for low-grade dysplasia that has been completely removed * Has had major surgery within 3 months before Screening or has a major surgery (ie, surgical procedure requiring general anesthesia) planned during the study * Has received protocol-specified prohibited medications
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.
Study sites(38)
Clinnova Research ( Site 1042)
Anaheim, California, United States
Recruiting
Southern California Research Center ( Site 1044)
Coronado, California, United States
Recruiting
Peak Gastroenterology Associates ( Site 1052)
Colorado Springs, Colorado, United States
Recruiting
South Denver Gastroenterology, PC ( Site 1068)
Englewood, Colorado, United States
Recruiting
Nature Coast Clinical Research ( Site 1045)
Inverness, Florida, United States
Recruiting
Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072)
Miami, Florida, United States
Recruiting
AdventHealth Orlando ( Site 1074)
Orlando, Florida, United States
Recruiting
Gastroenterology Associates of Central Georgia ( Site 1060)
Macon, Georgia, United States
Recruiting
University of Kansas Medical Center ( Site 1077)
Kansas City, Kansas, United States
Recruiting
Tulane University School of Medicine-Gastroenterology and Hepatology ( Site 1073)
New Orleans, Louisiana, United States
Recruiting
BVL Research - Kansas ( Site 1054)
Liberty, Missouri, United States
Recruiting
Prairie Institute of Liver and Luminal Advanced Research ( Site 1008)
Lethbridge, Alberta, Canada
Recruiting
Toronto Western Hospital ( Site 1006)
Toronto, Ontario, Canada
Recruiting
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 1001)
Montreal, Quebec, Canada
Recruiting
Servicios de Salud IPS Suramericana S.A.S. - IPS Sura Industriales Medellín ( Site 1163)
Medellín, Antioquia, Colombia
Recruiting
Clinica de la Costa S.A.S. ( Site 1161)
Barranquilla, Atlántico, Colombia
Recruiting
Fundacion Santa Fe de Bogota ( Site 1165)
Bogota, Cundinamarca, Colombia
Recruiting
Fundación Valle del Lili ( Site 1162)
Cali, Valle del Cauca Department, Colombia
Recruiting
Centre Hospitalier Dr Schaffner ( Site 1288)
Lens, Pas-de-Calais, France
Recruiting
Clinique Jules Verne ( Site 1284)
Nantes, Pays de la Loire Region, France
Recruiting
Universitaetsklinikum Ulm. ( Site 1324)
Ulm, Baden-Wurttemberg, Germany
Recruiting
Evangelismos General Hospital of Athens ( Site 1362)
Athens, Attica, Greece
Recruiting
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 1361)
Athens, Attica, Greece
Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1404)
Bologna, Emilia-Romagna, Italy
Recruiting
Radboudumc ( Site 1650)
Nijmegen, Gelderland, Netherlands
Recruiting
Amsterdam UMC, locatie VUmc ( Site 1651)
Amsterdam, North Holland, Netherlands
Recruiting
PROMED P. LACH R. GLOWACKI SP. J. ( Site 1447)
Krakow, Lesser Poland Voivodeship, Poland
Recruiting
Melita Medical Sp Zoo ( Site 1442)
Wroclaw, Lower Silesian Voivodeship, Poland
Recruiting
EB Group Sp. Z o.o. Centrum Zdrowia MDM ( Site 1449)
Warsaw, Masovian Voivodeship, Poland
Recruiting
Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś ( Site 1448)
Warsaw, Masovian Voivodeship, Poland
Recruiting
Twoja Przychodnia - Szczeciskie Centrum Medyczne ( Site 1450)
Szczecin, West Pomeranian Voivodeship, Poland
Recruiting
Wonju Severance Christian Hospital ( Site 1602)
Wŏnju, Kang-won-do, South Korea
Recruiting
Korea University Ansan Hospital ( Site 1603)
Ansan-si, Kyonggi-do, South Korea
Recruiting
Kangbuk Samsung Hospital ( Site 1601)
Seoul, South Korea
Recruiting
Addenbrooke's Hospital ( Site 1525)
Cambridge, Cambridgeshire, United Kingdom
Recruiting
Fairfield General Hospital ( Site 1524)
Bury, Lancashire, United Kingdom
Recruiting
Guys and St Thomas NHS Foundation Trust ( Site 1523)
London, London, City of, United Kingdom
Recruiting
Huddersfield Royal Infirmary ( Site 1522)
Huddersfield, York, United Kingdom
Recruiting
Showing 38 of 38 sites. 38 of the 38 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07463183. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me